Vaxart oral Covid-19 vaccine: could trial execution obstacles delay market entry?
Vaxart’s vaccine could sidestep antivector response concerns and has potential to prevent transmission.
Approvals
Regulatory roundup: AbbVie’s Phase II fail plunges Alzheimer’s contender’s shot at further study
Avalo in Crohn’s disease and RemeGen in Berger’s disease are also reviewed by GlobalData’s Investigative...
Vaccination in children aged 5–11 years will likely cut Covid-19 mortality in the US
A high vaccination rate in children aged five to 11 years may help reduce Covid-19...
More promise for psilocybin in depression but safety remains a concern
Psilocybin showed positive signs as a potential treatment for neurological conditions, but safety concerns need...
In conversation: nonalcoholic steatohepatitis investigator Rohit Loomba
Top NASH investigator Rohit Loomba discusses the potential of imaging in replacing biopsies, and much...
Enlivex obtains approval for Covid-19 therapy trial expansion to Spain
Phase IIb trail will assess the efficacy and safety of Allocetra when given in addition to the standard of care therapy.
Vaxine to file for Australian approval of protein subunit Covid-19 vaccine
An Iran-staged trial shows SpikoGen exceeded the 60% efficacy bar in the primary endpoint of prevention of symptomatic disease.
Regulatory roundup: Roche’s ulcerative colitis asset plunges after Phase I terminated
Eli Lilly’s lebrikizumab in eczema and AbbVie in blood cancers are among other assets reviewed by GlobalData’s Investigative News team.
ALS pipeline suffers a major hit as Biogen’s Tofersen fails phase iii trial
Biogen's Tofersen did not meet its efficacy results in the Phase III VALOR study for ALS, which reflects the struggle to find treatments for this disease.
Roche’s Tecentriq enjoys first-mover advantage in adjuvant NSCLC
While Tecentriq should initially capture a small share of the NSCLC market, significant long-term competition can be expected.
Competition grows to be the next disease-modifying therapy for Alzheimer’s disease
There is a number of DMT therapies for AD that are at the last stages of development, with Roche's gantenerumab acquiring BTD status in October.
